<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="92">
  <stage>Registered</stage>
  <submitdate>1/08/2005</submitdate>
  <approvaldate>5/08/2005</approvaldate>
  <actrnumber>ACTRN12605000086662</actrnumber>
  <trial_identification>
    <studytitle>Effects of circadian disruption and sleep deprivation in respiratory disorders</studytitle>
    <scientifictitle>Effects of circadian disruption on neurobehavioural and physiological variables in patients with respiratory disorders and healthy controls.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnea</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To determine the effect of acute circadian disruption (simulated jet-lag-2 days) on a range of neurobehavioural and physiological variables in patients with obstructive sleep apnea or asthma.</interventions>
    <comparator>Healthy control subjects.</comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The total number of lapses (defined as RT&gt; 500ms) during a 10-min psychomotor vigilance task (PVT)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean slowest 10% metric of the PVT during a 10-min psychomotor vigilance task (PVT)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subjective sleepiness as determined by the KSS</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Rsr and expired NO, and changes in RDI and sleep architecture during the period of circadian disruption, compared to baseline values in patients and to effects in healthy control subjects during circadian disruption.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Other measures of neurocognitive functioning, including working memory function, cognitive throughput, arithmetic and time estimation.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other measures of subjective alertness and functioning capabilities.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Core body temperature for circadian phase assessments.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective levels of alertness measuring using the waking EEG.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>OSA: Untreated subjects with moderate to severe OSA (RDI &gt; 30).
Asthma: Asthmatic subjects (ATS Criteria) will be recruited from asthma clinics associated with AIs. We will use clinic patients (current non-smokers and minimal smoking history)with moderate to severe asthma based on NAC guidelines i.e. those requiring short acting beta agonists 3 or more days week or with nocturnal symptoms more than once per fortnight. 
Controls: We will recruit healthy controls.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>OSA: use of alcohol&gt; 40gm/day, psychotropic medication, intercurrent asthma, other unstable medical conditions or evidence of clinically significant awake respiratory failure. 
Asthma:We will exclude subjects on long-acting bronchodilators (salmeterol, formoterol, tiotropium and theophylline). Inhaled corticosteroids will be held constant from screening into studies and use of short acting beta agonists will be permitted and monitored during protocols.
 Controls: similar exclusion criteria as for the OSA and asthma subjects
Subjects with the presence of asthma (ATS criteria) and OSA will be excluded. The absence of OSA will be determined using a validated nocturnal respiratory monitor over 2 nights (Autoset T, ResMed).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/10/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council (NHMRC) project funding</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC fellowship</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NSW BioFirst Award</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Prince Alfred Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Services Ethics Review Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Sydney Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Naomi Rogers</name>
      <address>PO Box M77 
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 93510906</phone>
      <fax>+61 2 93510914</fax>
      <email>nrogers@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>PO Box M77 
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>volunteers@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>